Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Twist Bioscience has the GF Score of 69, which implies that the company
might have
Poor future performance potential.
The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.
GF Score takes following five key aspects into consideration:
Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.
Based on research and backtesting result, GuruFocus believes Twist Bioscience
might have
Poor future performance potential.
Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.
Twist Bioscience (NAS:TWST) GF Score Explanation
Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:
GF Score
Performance Potential and All-in-One Screener Examples (1)
(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.
Twist Bioscience GF Score Related Terms
TWST vs BLLN, SHC, VCYT: GF Score Comparison
For the Diagnostics & Research subindustry, Twist Bioscience's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Twist Bioscience GF Score vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Twist Bioscience's GF Score distribution charts can be found below:
* The bar in red indicates where Twist Bioscience's GF Score falls into.
Twist Bioscience (TWST) has a GF Score of 69 as of Jul. 22, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Twist Bioscience and its competitors. This is 11% above median its historical median of 62.00. Over the past decade, Twist Bioscience's GF Score has ranged from 14.00 to 86.00.
Is Twist Bioscience's GF Score too high?
Twist Bioscience's current GF Score of 69 is 11% above median its 10-year median of 62.00. Over the past 10 years, this metric has ranged from a low of 14.00 to a high of 86.00. Overall, Twist Bioscience has a GF Score™ of 69/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Twist Bioscience's GF Score compare to BLLN and SHC?
Twist Bioscience's GF Score of 69 can be compared against companies in the Medical Diagnostics & Research industry. Historically, Twist Bioscience's own GF Score has ranged from 14.00 to 86.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Medical Diagnostics & Research company?
A good GF Score depends on the Medical Diagnostics & Research industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Twist Bioscience and its competitors. Twist Bioscience's current GF Score is 69, which is 11% above median its own 10-year median of 62.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Twist Bioscience stock overvalued right now?
Based on GuruFocus' analysis, Twist Bioscience (TWST) is currently considered Significantly Overvalued. The stock's GF Value™ is $48.36, compared to a current price of $94.21 — trading 94.8% above its estimated fair value. The current GF Score is 69, which is 11% above median its 10-year median of 62.00. Twist Bioscience's overall GF Score™ is 69/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For Twist Bioscience (TWST), the current GF Score is 69 as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Twist Bioscience (TWST) Overvalued in 2026?
Based on GuruFocus' analysis, Twist Bioscience stock appears to be overvalued.
The current stock price of $94.21 is trading 94.8% above its estimated GF Value™ of $48.36.
GuruFocus considers Twist Bioscience to be Significantly Overvalued.
Key valuation signals for TWST:
GF Score: 69 (11% above median its 10-year median of 62.00)
GF Value™: $48.36 vs. price of $94.21 (94.8% above fair value)
No single metric tells the full story. See the TWST stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Twist Bioscience Corp is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's proprietary semiconductor-based manufacturing process synthesizes DNA on silicon rather than traditional plastic plates, enabling the production of high-quality synthetic DNA faster, more affordably, and at scale. This platform overcomes conventional inefficiencies, supports cost-effective, high-throughput synthesis, and allows researchers to accelerate innovation. Geographically, the company operates across the Americas, EMEA, and APAC, deriving the majority of its revenue from the Americas.
69GF Score
Get the complete analysis for TWST
GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TWST has been successfully added to your 
